Factors contributing to the improvement in J-HAQ after 3 years of treatment with abatacept in biologic-naïve rheumatoid arthritis patients: Interim results of a long-term, observational, multicentre study in Japan (ORIGAMI).

Kenta MisakiEiichi TanakaEisuke InoueNaoto TamuraFuminori HiranoYoshinori TaniguchiHiroshi SatoTaio NaniwaHideto OshikawaTamami YoshitamaYuya TakakuboYoko SuzukiShinkichi HimenoKatsuki TsuritaniShigeru MatsumotoHisashi YamanakaMasayoshi Harigai

Published in: Modern rheumatology (2024)

This study confirmed the 3-year effectiveness and safety, and revealed potential factors associated with J-HAQ remission in biologic-naïve RA patients treated with abatacept in real-world clinical practice.

Keyphrases

rheumatoid arthritis
disease activity
rheumatoid arthritis patients
ankylosing spondylitis
clinical practice
systemic lupus erythematosus
interstitial lung disease
single cell
risk assessment
climate change